TrialCell reports. Medicine2025

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

Tingwei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.